UPDATED: CRL on the way? Acadia reports a surprise hitch in its quest to expand the market for Nuplazid — shares routed
A group of enthusiastic analysts cheering on Acadia’s share price $ACAD might have to take a knee.
The biotech, which has been whipping up enthusiasm on the investor circuit with prospects of expanding its franchise for Nuplazid with an OK for dementia-related psychosis, announced Monday after the market closed that the FDA had identified unspecified “deficiencies” in its sNDA for the drug that forbade any discussions about labeling and post-marketing requirements.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.